Patent Number: 7,202,207

Title: Indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals

Abstract: The present invention relates to the use of a composition comprising at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit, in the manufacture of a medicament for prophylaxis and/or treatment of infection. In particular the invention relates to prophylaxis and/or treatment of infection in an individual having an immunocompromised condition; and/or an individual being at risk of acquiring an immunocompromised condition resulting from a medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of infection in individuals suffering from neutropenia, in particular as prophylaxis and/or treatment of infection in individuals receiving or going to receive chemotherapy or similar treatment. The individuals may be treated independent on their serum MBL level, and it has been shown that in particular individuals having a serum MBL level in the range of from 50 ng/ml serum to 500 ng/ml serum may benefit from the prophylaxis and/or treatment.

Inventors: Thiel; Steffen (DK-8240 Risskov, DK), Jensenius; Jens Christian (DK-5230 Odense, DK)

Assignee:

International Classification: C07K 14/00 (20060101); A61K 38/00 (20060101); A61K 38/16 (20060101)

Expiration Date: 2019-04-10 0:00:00